Popovits Kimberly J 4

What Happened

• Kimberly J. Popovits, a director of Kiniksa Pharmaceuticals International (KNSA), was granted and vested restricted share units (RSUs) and executed option/derivative activity on May 29, 2026.
• She was awarded/vested a total of 14,184 RSUs (12,158 + 2,026) reported as derivative awards at $0.00 per unit, and there was an exercise/conversion of 2,799 option/derivative shares. The filing also shows a simultaneous disposition of 2,799 derivative shares. No market prices or cash values were reported in the filing for these transactions.

Key Details

• Transaction dates: May 29, 2026 (filed on June 2, 2026). Filing appears timely (within the standard 2 business-day Form 4 window).
• Transaction codes: A = Award/Grant (RSUs); M = Exercise or conversion of derivative securities.
• Prices reported: RSUs shown at $0.00 per unit (derivative awards); one exercise entry shows price N/A and the disposition shows $0.00 — no cash value or open-market sale proceeds are reported.
• Shares owned after the reported transactions: not specified in the excerpt provided.
• Relevant footnotes:
  • F1: Each RSU equals a contingent right to one Class A ordinary share.
  • F3/F4: The RSUs vested in their entirety on May 29, 2026 (single installment; no expiration).
  • F2: The related option vests in monthly installments starting from the May 29, 2026 grant date (final installment by the earlier of the one-year anniversary or the next annual meeting).

Context

• These were derivative transactions (awards and an exercise/conversion), not open-market purchases. The filing does not state the purpose of the immediate disposition of the 2,799 shares (e.g., tax withholding or sale), so no conclusion about sentiment should be drawn.
• Awards (RSUs vesting) are non-cash compensation and reflect grant/vesting events rather than purchases; purchases are typically viewed as more direct bullish signals for retail investors.